Why the study?
Do intravenous streptokinase, oral aspirin, and intravenous heparin reduce mortality, reinfarction, and stroke in patients with suspected acute myocardial infarction?
Population
619 patients with suspected acute myocardial infarction (MI)
Comparison
Intravenous streptokinase, oral aspirin, and… vs Placebo, placebo, and no heparin
Design
RCT, 2 × 2 × 2 factorial design, Placebo-controlled for streptokinase and…
Follow-up
In hospital and after discharge
Authors
Loading...
Supports aspirin and streptokinase in suspected AMI; extends evidence and informs larger confirmatory trials.
Do intravenous streptokinase, oral aspirin, and intravenous heparin reduce mortality, reinfarction, and stroke in patients with suspected acute myocardial infarction?
This pilot study demonstrated the potential mortality benefit of aspirin and the stroke reduction benefit of streptokinase in acute myocardial infarction, paving the way for the landmark ISIS-2 trial.
ISIS PILOT STUDY INVESTIGATION (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: